Status:
UNKNOWN
GFAP Auto-immunity : a French Cohort Study
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Autoimmune GFAP Astrocytopathy
Eligibility:
All Genders
Brief Summary
Glial fibrillary acidic protein (GFAP)-Immunoglobulin G (IgG) have recently been described as a biomarker of a novel inflammatory central nervous system (CNS) disorder, termed autoimmune GFAP astrocyt...
Eligibility Criteria
Inclusion
- Positive GFAP-Ab in serum and/or CSF tested by immunohistochemistry on mouse brain slices and confirmed by cell-based assay (CBA) of HEK293 cells expressing GFAP.
- Diagnosis and follow-up in France
- No age limit : from 0 to unlimited age
Exclusion
- Patients GFAP-IgG negative in serum and CSF
- Absence of complete clinicopathological data
- Foreign follow-up
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04463550
Start Date
September 1 2019
End Date
November 1 2020
Last Update
July 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Bron, France, 69250